Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on September 23, 2025
Raising the Bar on Accessibility: Boyd’s New OMS Chair Meets Latest ADA Standard
Boyd’s S2617 OMS Chair, revealed at AAOMS 2025, complies with new ADA transfer height standards and elevates accessibility in oral surgery. CLEARWATER, FL, UNITED STATES, September 23, 2025 /EINPresswire.com/ -- Boyd Industries, the leading manufacturer …
Identifyn® Launches Groundbreaking Super-Resolution Biology Platform
SARASOTA, FL, UNITED STATES, September 23, 2025 /EINPresswire.com/ -- Identifyn®, a pioneer in super-resolution imaging applications and discovery tools, today announced the debut of its innovative product line designed to transform biological imaging …
Designing Spaces® of Hope to Air Special Edition Featuring Care Camps Foundation & Happiness Is Camping on Lifetime TV
The special will premiere on Lifetime Television on September 24 at 7:30 AM ET/PT FORT LAUDERDALE, FL, UNITED STATES, September 23, 2025 /EINPresswire.com/ -- Designing Spaces® of Hope, the award-winning home improvement and community-focused television …
AB Global Promotes Marci Williamson to Director of Finance to Support Continued Growth and Financial Excellence
AB Global, The Gold Standard in Background Screening®, is proud to announce the promotion of Marci Williamson to Director of Finance. ST. PETERSBURG, FL, UNITED STATES, September 23, 2025 /EINPresswire.com/ -- AB Global, The Gold Standard in Background …
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the …
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the …
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on September 22, 2025, the Lifecore compensation …
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court NANTES, France – September 23, 2025, 10:30 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) acknowledges the decision rendered on September 23, 2025, by …
OSE Immunotherapeutics prend acte de la décision du Tribunal de commerce de Nantes
OSE Immunotherapeutics prend acte de la décision du Tribunal de commerce de Nantes NANTES, France – 23 septembre 2025, 22 h 30 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) prend acte de la décision rendue le 23 septembre 2025 par le …
Natural Alternatives International, Inc. Announces Fiscal 2025 Q4 and YTD Results
CARLSBAD, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $7.2 million, or ($1 …
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company’s supplemental New Drug Application (sNDA) for the high …
Nyxoah Provides an Update on Expanded Middle East Presence
Nyxoah Provides an Update on Expanded Middle East Presence New Centers in Dubai, Kuwait, and Abu Dhabi Following First Genio® Implant in the Region Earlier in 2025 Mont-Saint-Guibert, Belgium – September 23, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA ( …
Nyxoah Présente les Dernières Avancées Concernant son Expansion au Moyen-Orient
Nyxoah Présente les Dernières Avancées Concernant son Expansion au Moyen-Orient De nouveaux centres à Dubaï, au Koweït et à Abu Dhabi après la première implantation de Genio® dans la région au début de l'année 2025 Mont-Saint-Guibert, Belgique – 23 …
Privia Health Expands Value-Based Care Footprint with Acquisition of Accountable Care Organization Business from Evolent Health
ARLINGTON, Va., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that it signed a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE: EVH). The ACO business …
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative …
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3 INDUCTION TRIALS: …
Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the …
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) …